Reply to A. J. Cmelak et al and B. Kalra et al

Affiliations

¹ Anupama Chundury, MD, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Pippa F. Cosper, MD, Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI; and Sung Kim, MD, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

Comment

Anupama Chundury et al. J Clin Oncol. 2021.

. 2021 Aug 20;39(24):2735-2736.

doi: 10.1200/JCO.21.00885. Epub 2021 May 27.

¹ Anupama Chundury, MD, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Pippa F. Cosper, MD, Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI; and Sung Kim, MD, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

No abstract available

Conflict of interest statement

Sung KimConsulting or Advisory Role: NanobiotixNo other potential conflicts of interest were reported.

Radiation Dose De-Escalation in HPV-Positive Oropharynx Cancer: When Will It Be an Acceptable Standard of Care?
Chundury A, Kim S. Chundury A, et al. J Clin Oncol. 2021 Mar 20;39(9):947-949. doi: 10.1200/JCO.21.00017. Epub 2021 Feb 12. J Clin Oncol. 2021. PMID: 33577355 No abstract available.
Treatment De-intensification for HPV-Positive Oropharynx Cancer: What Is Currently Acceptable?
Cmelak AJ, Ferris RL, Chen AM, Seiwert T, Burtness B. Cmelak AJ, et al. J Clin Oncol. 2021 Aug 20;39(24):2732-2733. doi: 10.1200/JCO.21.00594. Epub 2021 May 27. J Clin Oncol. 2021. PMID: 34043410 No abstract available.
De-Escalation in HPV: Near Yet Elusive.
Kalra B, Sinha S, Laskar SG. Kalra B, et al. J Clin Oncol. 2021 Aug 20;39(24):2733-2734. doi: 10.1200/JCO.21.00635. Epub 2021 May 27. J Clin Oncol. 2021. PMID: 34043416 No abstract available.